The iprivask market research report is one of a series of new reports that provides iprivask market statistics, including the iprivask industry's global market size, regional shares, competitors with an iprivask market share, detailed iprivask market segments, market trends and opportunities, and any further data you may need to thrive in the iprivask industry. This iprivask market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to healthcare awareness campaigns, increasing prevalence of cardiovascular diseases, growing aging population, demand for effective medicines, and increasing demand for healthcare. Major trends in the forecast period include shift toward minimally invasive surgeries, rising focus on personalized medicine, expansion into non-orthopedic applications, emergence of biosimilars, and technological advancements.
The increasing number of hip replacement surgeries is expected to drive the growth of the iprivask market in the future. Hip replacement surgery involves replacing a damaged or diseased hip joint with a prosthesis to alleviate pain and improve mobility, commonly performed for conditions such as osteoarthritis or fractures. The rise in hip replacement procedures is fueled by an aging population, rising obesity rates, and advancements in surgical techniques that enhance outcomes. Iprivask (desirudin) is used during hip replacement surgeries to prevent deep vein thrombosis (DVT), thus lowering the risk of blood clots. For example, in September 2023, Orthopedic Network News (ONN), a U.S.-based orthopedic news provider, reported that the number of hip procedures in the U.S. increased from 737,503 in 2021 to 765,558 in 2022, representing a 3.8% rise. Therefore, the growing number of hip replacement surgeries is driving the expansion of the iprivask market.
The increasing incidence of venous thromboembolism (VTE) among patients is expected to further propel the iprivask market. VTE is a condition where blood clots form in the veins, which can lead to deep vein thrombosis (DVT) or pulmonary embolism (PE). The rise in VTE cases is linked to factors such as an aging population, increasing risk factors such as obesity, immobility, and cancer, as well as improved detection methods. Iprivask (heparin sodium) is used to prevent and treat venous thromboembolism by inhibiting blood clot formation. For instance, according to the Centers for Disease Control and Prevention (CDC) in May 2024, VTE affects up to 900,000 people annually in the U.S., leading to 60,000 to 100,000 deaths each year, along with many others suffering from long-term complications. Consequently, the growing prevalence of VTE is contributing to the growth of the iprivask market.
The increasing healthcare expenditure is expected to drive the expansion of the iprivask market moving forward. Healthcare expenditure refers to total spending on medical goods, services, and public health initiatives within a specific period. This increase in spending is driven by factors such as an aging population, a higher prevalence of chronic and infectious diseases, medical technology advancements, and greater demand for quality healthcare services. Healthcare spending supports iprivask by funding research, improving access to medications, enhancing healthcare infrastructure, and ensuring better treatment delivery. For instance, in November 2024, Eurostat, a Luxembourg-based government agency, reported that healthcare expenditure in Europe rose from $1.69 trillion in 2021 to $1.75 trillion in 2022, marking a 3.6% increase due to rising demand and inflation. As a result, the growth in healthcare expenditure will continue to drive the iprivask market's expansion.
The key company operating in the iprivask market is Canyon Pharmaceuticals Inc.
North America was the largest region in the iprivask market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iprivask report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the iprivask market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Iprivask is a brand of low-molecular-weight heparin (LMWH) used as an anticoagulant to prevent and treat thromboembolic disorders. It works by inhibiting specific clotting factors in the blood. Iprivask is primarily used to reduce the risk of blood clots in conditions such as deep vein thrombosis (DVT).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main patient groups for iprivask include surgical patients, high-risk individuals, and elderly patients. Surgical patients are those undergoing procedures to treat or manage medical conditions. Iprivask is used in these patients to address needs such as managing blood loss, improving recovery, or targeting complications related to their condition (specific indications vary). It is commonly used for DVT prevention and treatment of established DVT, and it is distributed through various channels, including hospitals, specialty clinics, pharmacies, and online pharmacies.
The iprivask market consists of sales of iprivask 15 mg (desirudin for injection). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to healthcare awareness campaigns, increasing prevalence of cardiovascular diseases, growing aging population, demand for effective medicines, and increasing demand for healthcare. Major trends in the forecast period include shift toward minimally invasive surgeries, rising focus on personalized medicine, expansion into non-orthopedic applications, emergence of biosimilars, and technological advancements.
The increasing number of hip replacement surgeries is expected to drive the growth of the iprivask market in the future. Hip replacement surgery involves replacing a damaged or diseased hip joint with a prosthesis to alleviate pain and improve mobility, commonly performed for conditions such as osteoarthritis or fractures. The rise in hip replacement procedures is fueled by an aging population, rising obesity rates, and advancements in surgical techniques that enhance outcomes. Iprivask (desirudin) is used during hip replacement surgeries to prevent deep vein thrombosis (DVT), thus lowering the risk of blood clots. For example, in September 2023, Orthopedic Network News (ONN), a U.S.-based orthopedic news provider, reported that the number of hip procedures in the U.S. increased from 737,503 in 2021 to 765,558 in 2022, representing a 3.8% rise. Therefore, the growing number of hip replacement surgeries is driving the expansion of the iprivask market.
The increasing incidence of venous thromboembolism (VTE) among patients is expected to further propel the iprivask market. VTE is a condition where blood clots form in the veins, which can lead to deep vein thrombosis (DVT) or pulmonary embolism (PE). The rise in VTE cases is linked to factors such as an aging population, increasing risk factors such as obesity, immobility, and cancer, as well as improved detection methods. Iprivask (heparin sodium) is used to prevent and treat venous thromboembolism by inhibiting blood clot formation. For instance, according to the Centers for Disease Control and Prevention (CDC) in May 2024, VTE affects up to 900,000 people annually in the U.S., leading to 60,000 to 100,000 deaths each year, along with many others suffering from long-term complications. Consequently, the growing prevalence of VTE is contributing to the growth of the iprivask market.
The increasing healthcare expenditure is expected to drive the expansion of the iprivask market moving forward. Healthcare expenditure refers to total spending on medical goods, services, and public health initiatives within a specific period. This increase in spending is driven by factors such as an aging population, a higher prevalence of chronic and infectious diseases, medical technology advancements, and greater demand for quality healthcare services. Healthcare spending supports iprivask by funding research, improving access to medications, enhancing healthcare infrastructure, and ensuring better treatment delivery. For instance, in November 2024, Eurostat, a Luxembourg-based government agency, reported that healthcare expenditure in Europe rose from $1.69 trillion in 2021 to $1.75 trillion in 2022, marking a 3.6% increase due to rising demand and inflation. As a result, the growth in healthcare expenditure will continue to drive the iprivask market's expansion.
The key company operating in the iprivask market is Canyon Pharmaceuticals Inc.
North America was the largest region in the iprivask market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iprivask report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the iprivask market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Iprivask is a brand of low-molecular-weight heparin (LMWH) used as an anticoagulant to prevent and treat thromboembolic disorders. It works by inhibiting specific clotting factors in the blood. Iprivask is primarily used to reduce the risk of blood clots in conditions such as deep vein thrombosis (DVT).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main patient groups for iprivask include surgical patients, high-risk individuals, and elderly patients. Surgical patients are those undergoing procedures to treat or manage medical conditions. Iprivask is used in these patients to address needs such as managing blood loss, improving recovery, or targeting complications related to their condition (specific indications vary). It is commonly used for DVT prevention and treatment of established DVT, and it is distributed through various channels, including hospitals, specialty clinics, pharmacies, and online pharmacies.
The iprivask market consists of sales of iprivask 15 mg (desirudin for injection). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Iprivask Market Characteristics4. Iprivask Market Trends And Strategies5. Iprivask Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Iprivask Pricing Analysis & Forecasts30. Global Iprivask Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Iprivask Market32. Recent Developments In The Iprivask Market
3. Iprivask Market Biologic Drug Characteristics
6. Global Iprivask Growth Analysis And Strategic Analysis Framework
8. Iprivask Market Segmentation
9. Global Iprivask Epidemiology Of Clinical Indications
10. Iprivask Market Regional And Country Analysis
11. Asia-Pacific Iprivask Market
12. China Iprivask Market
13. India Iprivask Market
14. Japan Iprivask Market
15. Australia Iprivask Market
16. South Korea Iprivask Market
17. Western Europe Iprivask Market
18. UK Iprivask Market
19. Germany Iprivask Market
20. France Iprivask Market
21. Eastern Europe Iprivask Market
22. North America Iprivask Market
23. USA Iprivask Market
24. Canada Iprivask Market
25. South America Iprivask Market
26. Middle East Iprivask Market
27. Africa Iprivask Market
28. Iprivask Market Competitive Landscape And Company Profiles
29. Global Iprivask Market Pipeline Analysis
33. Iprivask Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Iprivask Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on iprivask market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for iprivask ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The iprivask market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Patient Demographics: Surgical Patients; High-Risk Patients; Elderly Patients2) By Application: Deep Vein Thrombosis Prevention; Treatment Of Established Deep Vein Thrombosis Prevention
3) By Distribution Channel: Hospitals; Specialty Clinics; Pharmacies; Online Pharmacies
Key Companies Profiled: Canyon Pharmaceuticals Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Canyon Pharmaceuticals Inc.
